Upexi Inc
UPXI4.910USD
+0.140+2.94%
Close 10/24, 16:00（ET）Quotes delayed by 15 min
187.91MMarket Cap
LossP/E TTM
More Details of Upexi Inc Company
Upexi, Inc. is a brand owner specialized in the development, manufacturing and distribution of consumer products. The Company focuses on direct-to-consumer and Amazon brands. The Company’s brands include LuckyTail, PRAX, Cure Mushrooms, Moonwlkr, Gumi Labs, and Upexi Distribution. LuckyTail products consist of its flagship nail grinder and healthy all-natural pet supplements. Gumi Labs manufactures gummies and other products supporting its health and wellness products, including those products manufactured with hemp ingredients. Upexi Distribution manages the warehousing and logistic needs of the Company and provides storage, consolidation, assembly, Amazon preparation, distribution and fulfilment services to its brands and its manufacturing operation.
Upexi Inc Info
Ticker SymbolUPXI
Company nameUpexi Inc
IPO dateJun 24, 2021
CEO- -
Number of employees64
Security typeOrdinary Share
Fiscal year-endJun 24
Address3030 Rocky Point Drive
CityTAMPA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33607
Phone17013535425
Websitehttps://upexi.com/
Ticker SymbolUPXI
IPO dateJun 24, 2021
CEO- -
Company Executives of Upexi Inc
Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+899.43%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
585.37K
+60.32%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
349.14K
+252.17%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+899.43%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
585.37K
+60.32%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
349.14K
+252.17%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
9.26M
62.48%
Contract manufactured
2.79M
18.80%
Purchased as finished goods
2.78M
18.73%
By RegionUSD
Name
Revenue
Proportion
United States of America
14.57M
98.25%
Other
259.57K
1.75%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
9.26M
62.48%
Contract manufactured
2.79M
18.80%
Purchased as finished goods
2.78M
18.73%
Shareholding Stats
Updated: Sat, Oct 18
Updated: Sat, Oct 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MMCAP Asset Management
21.98%
Samara Special Opportunities
7.69%
GSR Growth Investments LP
3.92%
Marshall (Allan)
2.57%
Pantera Capital Partners LP
2.26%
Other
61.59%
Shareholders
Shareholders
Proportion
MMCAP Asset Management
21.98%
Samara Special Opportunities
7.69%
GSR Growth Investments LP
3.92%
Marshall (Allan)
2.57%
Pantera Capital Partners LP
2.26%
Other
61.59%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.83%
Corporation
11.61%
Individual Investor
5.95%
Investment Advisor
5.51%
Investment Advisor/Hedge Fund
1.00%
Research Firm
0.26%
Bank and Trust
0.24%
Venture Capital
0.14%
Other
51.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
53
23.37M
39.68%
+23.17M
2025Q2
46
10.18M
21.50%
+7.63M
2025Q1
42
311.78K
28.56%
-35.31K
2024Q4
42
307.62K
23.29%
-32.82K
2024Q3
40
303.51K
29.16%
-55.91K
2024Q2
40
319.39K
30.68%
-45.58K
2024Q1
42
328.34K
32.32%
-46.59K
2023Q4
42
319.26K
31.43%
-34.26K
2023Q3
40
369.15K
37.28%
-46.01K
2023Q2
44
368.80K
38.85%
-28.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MMCAP Asset Management
12.94M
21.98%
+12.94M
--
Jul 16, 2025
Samara Special Opportunities
4.53M
7.69%
+4.53M
--
Aug 29, 2025
GSR Growth Investments LP
2.31M
3.92%
-1.00
-0.00%
Jun 30, 2025
Marshall (Allan)
1.51M
2.57%
+1.36M
+899.43%
Jul 16, 2025
Pantera Capital Partners LP
1.33M
2.26%
+1.33M
--
Jun 30, 2025
Rudick (Brian Benjamin)
838.60K
1.42%
+400.00K
+91.20%
Jul 16, 2025
Salkind (Gene)
585.37K
0.99%
+220.24K
+60.32%
Jul 16, 2025
NewGen Asset Management Limited
577.19K
0.98%
+577.19K
--
Jun 30, 2025
The Vanguard Group, Inc.
500.84K
0.85%
+500.84K
--
Jun 30, 2025
Kathmere Capital Management
2.19M
3.72%
+2.19M
--
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Date
Type
Ratio
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
